PMID- 36949942
OWN - NLM
STAT- MEDLINE
DCOM- 20230324
LR  - 20230328
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Transmission of Zika virus by dendritic cell subsets in skin and vaginal mucosa.
PG  - 1125565
LID - 10.3389/fimmu.2023.1125565 [doi]
LID - 1125565
AB  - Zika virus is a member of the Flaviviridae family that has caused recent 
      outbreaks associated with neurological malformations. Transmission of Zika virus 
      occurs primarily via mosquito bite but also via sexual contact. Dendritic cells 
      (DCs) and Langerhans cells (LCs) are important antigen presenting cells in skin 
      and vaginal mucosa and paramount to induce antiviral immunity. To date, little is 
      known about the first cells targeted by Zika virus in these tissues as well as 
      subsequent dissemination of the virus to other target cells. We therefore 
      investigated the role of DCs and LCs in Zika virus infection. Human monocyte 
      derived DCs (moDCs) were isolated from blood and primary immature LCs were 
      obtained from human skin and vaginal explants. Zika virus exposure to moDCs but 
      not skin and vaginal LCs induced Type I Interferon responses. Zika virus 
      efficiently infected moDCs but neither epidermal nor vaginal LCs became infected. 
      Infection of a human full skin model showed that DC-SIGN expressing dermal DCs 
      are preferentially infected over langerin+ LCs. Notably, not only moDCs but also 
      skin and vaginal LCs efficiently transmitted Zika virus to target cells. 
      Transmission by LCs was independent of direct infection of LCs. These data 
      suggest that DCs and LCs are among the first target cells for Zika virus not only 
      in the skin but also the genital tract. The role of vaginal LCs in dissemination 
      of Zika virus from the vaginal mucosa further emphasizes the threat of sexual 
      transmission and supports the investigation of prophylaxes that go beyond 
      mosquito control.
CI  - Copyright (c) 2023 Eder, Zijlstra-Willems, Koen, Kootstra, Wolthers and 
      Geijtenbeek.
FAU - Eder, Julia
AU  - Eder J
AD  - Department of Experimental Immunology, Amsterdam UMC location University of 
      Amsterdam, Amsterdam, Netherlands.
AD  - Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
FAU - Zijlstra-Willems, Esther
AU  - Zijlstra-Willems E
AD  - Department of Experimental Immunology, Amsterdam UMC location University of 
      Amsterdam, Amsterdam, Netherlands.
FAU - Koen, Gerrit
AU  - Koen G
AD  - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC 
      location University of Amsterdam, Amsterdam, Netherlands.
FAU - Kootstra, Neeltje A
AU  - Kootstra NA
AD  - Department of Experimental Immunology, Amsterdam UMC location University of 
      Amsterdam, Amsterdam, Netherlands.
AD  - Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
FAU - Wolthers, Katja C
AU  - Wolthers KC
AD  - Department of Medical Microbiology and Infection Prevention, Amsterdam UMC 
      location University of Amsterdam, Amsterdam, Netherlands.
FAU - Geijtenbeek, Teunis B
AU  - Geijtenbeek TB
AD  - Department of Experimental Immunology, Amsterdam UMC location University of 
      Amsterdam, Amsterdam, Netherlands.
AD  - Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230306
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Female
MH  - Humans
MH  - Dendritic Cells
MH  - *Zika Virus
MH  - Langerhans Cells
MH  - Epidermis/metabolism
MH  - Mucous Membrane
MH  - *Zika Virus Infection/metabolism
PMC - PMC10025456
OTO - NOTNLM
OT  - Langerhans cells
OT  - Zika virus
OT  - vaginal mucosa
OT  - viral dissemination
OT  - virus transmission
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/24 06:00
MHDA- 2023/03/25 06:00
PMCR- 2023/01/01
CRDT- 2023/03/23 02:18
PHST- 2022/12/16 00:00 [received]
PHST- 2023/02/23 00:00 [accepted]
PHST- 2023/03/23 02:18 [entrez]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/25 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1125565 [doi]
PST - epublish
SO  - Front Immunol. 2023 Mar 6;14:1125565. doi: 10.3389/fimmu.2023.1125565. 
      eCollection 2023.